Company: ABUS
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012305
Chunk: 38

Company: Arbutus Biopharma Corp
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 38
---
 — |     |         | — |     |       |       — |     |         |       — |     |         |       — |     |                |      — |     |              |         — |     |           |
| Michael J. Sofia, Ph.D.(8)   
 Former Chief Scientific      
 Officer                      |      |     | 2024 |         |     | 512,000 |   |     | —     |         |     | 262,800 |         |     | 814,818 |         |     |        204,800 |        |     |       25,636 |           |     | 1,820,054 |
|                              | 2023 |     |      | 492,000 |     |         | — |     |       | 238,380 |     |         | 720,208 |     |         | 147,600 |     |                | 16,500 |     |              | 1,614,688 |     |           |

| (1) | The amounts in this column represent the aggregate grant date fair value of the restricted stock unit grants, calculated in accordance with Financial Accounting Standards Board, Accounting Standards Codification (“ASC”) Topic 718. These amounts do not necessarily correspond to the actual value that may be realized by the executive in connection with his or her restricted stock unit awards. The assumptions made in valuing the restricted stock unit awards reported in this column are described in our audited consolidated financial statements (Note 13, Stock-based compensation) included in our Annual Report. |

| (2) | The amounts in this column represent the aggregate grant date fair value of the option grants, calculated in accordance with ASC Topic 718. These amounts do not necessarily correspond to the actual value that may be realized by the executive in connection with his or her option awards. The assumptions made in valuing the option awards reported in this column are described in our audited consolidated financial statements (Note 13, Stock-based compensation) included in our Annual Report. |

| (3) | The amounts in this column represent performance bonuses earned by the Named Executive Officers in the year shown based upon the achievement of pre-established performance objectives. See “Non-Equity Incentive Plan Compensation” below. |

| (4) | The amounts in this column for 2024 and 2023 include 401(k) matching contributions for each Named Executive Officer in the year shown in accordance with company policy. |

| (5)